Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|May 23, 2007

Kythera Appoints CMO

Kythera Biopharmaceuticals, Inc. (Calabasas, CA, www.kytherabiopharma.com), has appointed Patricia Walker, MD, PhD, as chief medical officer and vice president of clinical development and regulatory affairs.

Kythera Biopharmaceuticals, Inc. (Calabasas, CA, www.kytherabiopharma.com), has appointed Patricia Walker, MD, PhD, as chief medical officer and vice president of clinical development and regulatory affairs. Walker, who brings to Kythera more than 10 years of industry experience, will lead clinical programs at Kythera.


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.